한빛사 논문
Jiyun Leea, Yoon La Choib, Joungho Hanb, Sehhoon Parka, Hyun Ae Junga, Jong-Mu Suna, Se-Hoon Leea, Jin Seok Ahna, Keunchil Parka, Myung-Ju Ahna,*
aDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
bDepartment of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
*Corresponding author
Abstract
Introduction
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), efficiently penetrates the blood-brain barrier. Current study explored whether treatment with osimertinib leads to improved overall survival (OS) for EGFR-mutated NSCLC patients with leptomeningeal metastases (LM) compared with those not treated with osimertinib.
Methods
From October 2008 to October 2019, patients with EGFR-mutated NSCLC and cytologically confirmed LM were retrospectively analyzed for OS according to osimertinib treatment and T790M mutational status. OS was defined as the time from diagnosis of LM to death.
Results
For the 351 LM patients included in analysis, the median OS (mOS) was 8.1 months (95% confidence interval [CI] 7.2–9.0). T790M mutation was detected in 88 of 197 patients tested, and a total of 110 patients were treated with osimertinib after LM. No significant difference in mOS was demonstrated according to T790M mutational status (10.1 months [95% CI 4.31–15.82] vs. 9.0 [6.81–11.21], P= 0.936). However, patients treated with osimertinib showed a superior OS of 17.0 months (95% CI, 15.13–18.94) compared with those not treated with osimertinib who showed a mOS 5.5 months (95% CI 4.34–6.63) regardless of T790M mutational status (HR 0.36; 95% CI 0.28–0.47, P <0.001). This was considerably longer even compared to those who were never treated with osimertinib but with first-/second-generation EGFR TKIs showing a mOS of 8.7 months (95% CI 7.01–10.39).
Conclusions
Osimertinib is a promising treatment option for EGFR-mutated NSCLC with LM regardless of T790M mutational status.
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기